Invesco
AVBP icon

Invesco’s ArriVent BioPharma AVBP Stock Holding History

Invesco’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$552K Buy
23,941
+7,049
+42% +$159K ﹤0.01% 3123
2025
Q4 		$340K Buy
16,892
+1,876
+12% +$39K ﹤0.01% 3336
2025
Q3 		$277K Sell
15,016
-33
-0.2% -$648 ﹤0.01% 3448
2025
Q2 		$328K Sell
15,049
-81
-0.5% -$1.68K ﹤0.01% 3330
2025
Q1 		$280K Sell
15,130
-209
-1% -$5.12K ﹤0.01% 3383
2024
Q4 		$409K Buy
+15,339
New +$440K ﹤0.01% 3318

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco's AVBP Position: Q1 2026 in Review

Invesco increased its ArriVent BioPharma (AVBP) stake by 42% in Q1 2026, buying an estimated $159K and bringing the position to 23,941 shares worth $552K. The position accounts for ﹤0.01% of the portfolio, ranked #3123.

Invesco first reported a position in AVBP in Q4 2024 and has held it in 6 quarters since. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Invesco held 23,941 shares of ArriVent BioPharma worth $552K as of Q1 2026.
  • Invesco bought 7,049 ArriVent BioPharma shares in Q1 2026, an estimated $159K.
  • ArriVent BioPharma made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #3123 holding.
  • Invesco first reported a position in ArriVent BioPharma in Q4 2024 and has held it in 6 quarters since.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.